Needham Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)

Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics (AUTLResearch Report) today and set a price target of $7.00. The company’s shares closed yesterday at $1.77.

Blum covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Gamida Cell, and Geron. According to TipRanks, Blum has an average return of -24.4% and a 27.32% success rate on recommended stocks.

Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $11.00, which is a 521.47% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $5.92 and a one-year low of $1.60. Currently, Autolus Therapeutics has an average volume of 395.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Read More on AUTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More